EGFR and glioblastoma: An oHSV engineered to express EGFR antibody cetuximab linked to the chemotactic chemokine CCL5 enhanced chemotactic and activation immune cells, inhibited tumor EGFR signaling, reduced tumor size and prolonged survival in glioblastoma-bearing mouse models [135].